{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:58:42Z","timestamp":1785189522074,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.psym.2013.06.008","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T21:28:11Z","timestamp":1376083691000},"page":"98-100","source":"Crossref","is-referenced-by-count":13,"title":["Acute Mania Associated With Levetiracetam Treatment"],"prefix":"10.1016","volume":"55","author":[{"given":"Eliza M.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Reeder-Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.psym.2013.06.008_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2006.02.004","article-title":"Diverse mechanisms of antiepileptic drugs in the development pipeline","volume":"69","author":"Rogawski","year":"2006","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.psym.2013.06.008_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.psym.2013.06.008_bib3","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/j.1528-1167.2006.00819.x","article-title":"In situ metabolism of levetiracetam in blood of patients with epilepsy","volume":"47","author":"Patsalos","year":"2006","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.psym.2013.06.008_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.psym.2013.06.008_bib5","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.psym.2013.06.008_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/j.1950-6945.2003.tb00573.x","article-title":"Acute psychosis associated with levetiracetam","volume":"5","author":"Youroukos","year":"2003","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.psym.2013.06.008_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.pnpbp.2010.09.007","article-title":"Probable psychosis associated with levetiracetam: a case report","volume":"35","author":"Aggarwal","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.psym.2013.06.008_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4088\/JCP.09m05659gre","article-title":"Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Saricicek","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.psym.2013.06.008_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-008-1109-8","article-title":"Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study","volume":"198","author":"Kruger","year":"2008","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.psym.2013.06.008_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.yebeh.2004.08.009","article-title":"Monotherapy treatment of bipolar disorder with levetiracetam","volume":"5","author":"Kaufman","year":"2004","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.psym.2013.06.008_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncpneuro1051","article-title":"Can antiepileptic drugs unmask a susceptibility to psychiatric disorders?","volume":"5","author":"Kanner","year":"2009","journal-title":"Nat Clin Pract Neurol"},{"issue":"7","key":"10.1016\/j.psym.2013.06.008_bib12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4088\/JCP.v64n0707","article-title":"Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design","volume":"64","author":"Grunze","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psym.2013.06.008_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1176\/appi.ajp.159.1.148","article-title":"Levetiracetam for acute mania","volume":"159","author":"Goldberg","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.psym.2013.06.008_bib14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/01.WNL.0000091865.46063.67","article-title":"Discontinuation of levetiracetam because of behavioral side effects: a case-control study","volume":"61","author":"White","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.psym.2013.06.008_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.yebeh.2003.07.008","article-title":"Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases","volume":"4","author":"Dinkelacker","year":"2003","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.psym.2013.06.008_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pds.1871","article-title":"Antiepileptic drugs in Australia: 2002-2007","volume":"19","author":"Hollingworth","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.psym.2013.06.008_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318213001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318213001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T13:47:28Z","timestamp":1746020848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318213001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0033318213001084"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2013.06.008","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}